Compare Sana Biotechnology Inc (SANA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs STMicroelectronics NV — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while STMicroelectronics NV trades at $54.14 (market cap $49.21B). The key difference: STMicroelectronics NV is far larger — about 43.5× Sana Biotechnology Inc's market cap, and STMicroelectronics NV pays a 0.65% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | STM | |
|---|---|---|
Market Cap | $1.13B | $49.21B |
Sector | Health | Financials |
52-Week High | $5.92 | $79.91 |
52-Week Low | $2.68 | $21.20 |
Enterprise Value | $1.05B | $47.21B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
STM trades at $54.51, up 0.29% today, with a neutral technical signal and mixed earnings history. The stock shows a high P/E of 107.92 but benefits from strong cash flow and a solid balance sheet with $6.18B in cash. Recent news highlights AI data center growth potential, with management targeting over $2B in revenues by 2027, though Q3 2026 earnings expectations face scrutiny after past misses.
Outlook is cautiously optimistic with a consensus price target of $74.63, implying 37% upside, supported by 52% analyst buy ratings. Risks include execution challenges in AI initiatives, margin pressure from high capex, and sensitivity to semiconductor cycle downturns. Investor sentiment is balanced amid growth prospects and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
